Clinical Trails

Early results from an ongoing Phase 2 trial (NCT07222579) show that a subcutaneous (under-the-skin) form of blinatumomab (Blincyto) may be highly effective and well tolerated for mixed phenotype acute leukemia (MPAL), a rare and aggressive blood cancer. The first patient treated, a 77-year-old with Philadelphia chromosome–negative MPAL, achieved a complete response after just one 26-day […]

The SWOG S1512 Phase 2 trial studied giving pembrolizumab (Keytruda) before surgery to patients with resectable desmoplastic melanoma, a rare type of skin cancer usually found on sun-exposed areas. After just three doses of pembrolizumab, 71% of patients had no cancer left in their surgical tissue samples. At three years, 74% of patients had no

A phase 1/2 study evaluated tagraxofusp (Elzonris), a CD123-targeted therapy, as a single-agent treatment for patients with myelofibrosis. The drug showed modest clinical benefit but was generally well tolerated, with no dose-limiting toxicities reported. These findings suggest tagraxofusp may be better suited for use in combination with other therapies rather than as a standalone treatment.

Global trials are showing strong promise for PARP inhibitors as a new targeted treatment for advanced prostate cancer. Prostate cancer is the second most common cancer in men, with about 1.5 million new cases yearly and numbers expected to rise to 2.4 million by 2040. While early-stage prostate cancer has nearly a 100% 5-year survival

A new combination therapy for advanced urothelial cancer shows promising results, according to the Phase 2 TROPION-PanTumor03 trial. Datopotamab deruxtecan (Dato-DXd), a TROP2-targeted antibody-drug conjugate, was combined with rilvegostomig, a bispecific antibody against PD-1 and TIGIT, to enhance antitumor activity. In cisplatin-ineligible, first-line patients (n=22), the confirmed objective response rate (ORR) was 68.2%, with a

In Phase II study for extensive-stage small-cell lung cancer (ES-SCLC), the novel intercalated administration of the anti-PD-L1 inhibitor avelumab with platinum-etoposide chemotherapy (avelumab started after cycle 2) did not meet the primary endpoint of a 25% one-year progression-free survival (PFS), achieving 12.7% (median PFS: 5.8 months). Despite this, the treatment demonstrated high anti-tumor activity with an Objective Response

Large B-cell lymphoma (LBCL) is the most common aggressive non-Hodgkin lymphoma, with about 60% of patients cured by first-line therapy. Relapsed or refractory (R/R) patients have poor outcomes, with median survival around 6.3 months. Autologous CD19 CAR T-cell therapies help some patients but are limited by manufacturing delays, disease aggressiveness, and access barriers. Cemacabtagene ansegedleucel

Clinical trials are exploring a range of innovative therapies for bladder cancer, aiming to improve outcomes while preserving the bladder. Intravesical and Targeted Therapies: Oncolytic viruses like cretostimogene grenadenorepvec and EG-70 are designed to selectively kill cancer cells and activate the immune system. Novel drug delivery systems, such as TAR-210, release chemotherapy (e.g., erdafitinib) over time